首页> 外文期刊>Cancer letters >Synthesis and biological evaluation of N-biphenyl-nicotinic based moiety compounds: A new class of antimitotic agents for the treatment of Hodgkin Lymphoma
【24h】

Synthesis and biological evaluation of N-biphenyl-nicotinic based moiety compounds: A new class of antimitotic agents for the treatment of Hodgkin Lymphoma

机译:基于二苯基 - 烟碱的部分化合物的合成及生物学评价:一种新的霍奇金淋巴瘤治疗抗杀氧剂

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

We previously demonstrated that some N-biphenylanilides caused cell-cycle arrest at G2/M transition in breast cancer cells. Among them we choose three derivatives, namely PTA34, PTA73 and RS35 for experimentation in solid tumor cell lines, classical Hodgkin Lymphoma (cHL) cell lines and bona fide normal cell lines. Almost all tumor cells were sensitive to compounds in the nanomolar range whereas, they were not cytotoxic to normal ones. Interestingly the compounds caused a strong G2/M phase arrest in cHL cell lines, thus, here we investigated whether they affected the integrity of microtubules in such cells. We found that they induced a long prometaphase arrest, followed by induction of apoptosis which involved mitochondria. PTA73 and RS35 induced the mitotic arrest through the fragmentation of microtubules which prevented the kinethocore-mitotic spindle interaction and the exit from mitosis. PTA34 is instead a tubulin-targeting agent because it inhibited the tubulin polymerization as vinblastine. As such, PTA34 maintained the Cyclin B1-CDK1 regulatory complex activated during the G2/M arrest while inducing the inactivation of Bcl-2 through phosphorylation in Ser70, the degradation of Mcl-1 and a strong activation of BIML and SIMS proapoptotic isoforms. In addition PTA34 exerted an antiangiogenic effect by suppressing microvascular formation.
机译:我们之前证明了一些N-BIphylanilides在乳腺癌细胞中引起了G2 / M转变的细胞周期停滞。其中我们选择三种衍生物,即PTA34,PTA73和RS35,用于实验性肿瘤细胞系,经典霍奇金淋巴瘤(CHL)细胞系和真绒正常细胞系。几乎所有肿瘤细胞对纳摩尔范围内的化合物敏感,而它们不是正常的细胞毒性。有趣的是,该化合物在CHL细胞系中引起了强烈的G2 / M期捕获,因此我们研究了它们是否影响了这些细胞中微管的完整性。我们发现它们诱导了长期的Prometaphase骤停,然后诱导涉及线粒体的细胞凋亡。 PTA73和RS35通过微管的碎片诱导丝分裂骤体,所述微管的碎裂,防止了Kinethocore-丝分裂纺锤体相互作用和分枝滴虫的出口。 PTA34是靶向剂的靶向剂,因为它抑制了小管蛋白聚合为调温剂。这样,PTA34将Cyclin B1-CDK1调节络合物保持在G2 / M停滞期间活化,同时通过SER70中的磷酸化诱导Bcl-2的灭活,Mcl-1的降解和强化Bim1和SIMS Proadootic同种型的强化活化。此外,PTA34通过抑制微血管形成施加抗血管生成效果。

著录项

  • 来源
    《Cancer letters》 |2019年第2019期|共10页
  • 作者单位

    IRCCS Ist Tumori Giovanni Paolo II Expt Pharmacol Lab Viale O Flacco 65 I-70124 Bari Italy;

    IRCCS Ist Tumori Giovanni Paolo II Expt Pharmacol Lab Viale O Flacco 65 I-70124 Bari Italy;

    Univ Bari Dipartimento Farmacia Sci Farmaco Bari Italy;

    IRCCS Ist Tumori Giovanni Paolo II Expt Pharmacol Lab Viale O Flacco 65 I-70124 Bari Italy;

    IRCCS Ist Tumori Giovanni Paolo II Expt Pharmacol Lab Viale O Flacco 65 I-70124 Bari Italy;

    IRCCS Ist Tumori Giovanni Paolo II Expt Pharmacol Lab Viale O Flacco 65 I-70124 Bari Italy;

    IRCCS Ist Tumori Giovanni Paolo II Med Oncol Unit Bari Italy;

    IRCCS Ist Tumori Giovanni Paolo II Haematol Unit Bari Italy;

    Univ Bari Dipartimento Farmacia Sci Farmaco Bari Italy;

    IRCCS Ist Tumori Giovanni Paolo II Expt Pharmacol Lab Viale O Flacco 65 I-70124 Bari Italy;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 肿瘤学;
  • 关键词

    Novel microtubule-targeting agents; N-biphenylanilides; Hodgkin Lymphoma cell lines; Capillary morphogenesis;

    机译:新型微管靶向剂;in-Biphyl苯吡啶;霍奇金淋巴瘤细胞系;毛细血管形态发生;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号